Welcome to our dedicated page for Alps Group SEC filings (Ticker: ALPWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alps Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alps Group's regulatory disclosures and financial reporting.
Alps Group Inc filed a Form 6-K highlighting a peer-reviewed case series of its autologous Natural Killer (NK) cell therapy using an in-house culture protocol. The study in SAGE Open Medical Case Reports followed nine patients treated at ALPS Medical Centre between 2023 and 2024.
Patients were monitored for blood counts, liver function, hypersensitivity, inflammatory markers and tumor markers to evaluate safety and potential toxic or dose-dependent adverse reactions. The case series provided evidence of clinical tolerability of autologous NK cells produced with the company’s proprietary protocol and complied with Malaysian Good Clinical Practice and the Declaration of Helsinki.
The company also emphasized a patent-pending, antibody-free culture method that aims to enable cost-effective, large-scale production of highly pure NK cells using basic media and autologous plasma. These preliminary data, together with preclinical GLP findings, are intended to support future clinical investigations in a broader patient population.
Alps Group Inc filed a Form 6-K highlighting a peer-reviewed case series of its autologous Natural Killer (NK) cell therapy using an in-house culture protocol. The study in SAGE Open Medical Case Reports followed nine patients treated at ALPS Medical Centre between 2023 and 2024.
Patients were monitored for blood counts, liver function, hypersensitivity, inflammatory markers and tumor markers to evaluate safety and potential toxic or dose-dependent adverse reactions. The case series provided evidence of clinical tolerability of autologous NK cells produced with the company’s proprietary protocol and complied with Malaysian Good Clinical Practice and the Declaration of Helsinki.
The company also emphasized a patent-pending, antibody-free culture method that aims to enable cost-effective, large-scale production of highly pure NK cells using basic media and autologous plasma. These preliminary data, together with preclinical GLP findings, are intended to support future clinical investigations in a broader patient population.
Alps Group Inc reports a potential expansion of its exosome-related pipeline beyond its CELESOME(+) programme, based on a newly published retrospective clinical case series of nebulized human umbilical cord mesenchymal stem cell-derived exosomes in patients with asthma and chronic obstructive pulmonary disease.
The peer-reviewed report describes investigational, once-weekly inhaled dosing over five weeks using a medical-grade nebulizer, with observations that included improved pulmonary function, stable inflammatory markers, and no significant adverse effects. Management emphasizes these findings are preliminary and that larger, controlled studies are required, with no assurances on eventual clinical success or regulatory approval.
Alps Group Inc reports a potential expansion of its exosome-related pipeline beyond its CELESOME(+) programme, based on a newly published retrospective clinical case series of nebulized human umbilical cord mesenchymal stem cell-derived exosomes in patients with asthma and chronic obstructive pulmonary disease.
The peer-reviewed report describes investigational, once-weekly inhaled dosing over five weeks using a medical-grade nebulizer, with observations that included improved pulmonary function, stable inflammatory markers, and no significant adverse effects. Management emphasizes these findings are preliminary and that larger, controlled studies are required, with no assurances on eventual clinical success or regulatory approval.